Ligustrazine Affects the Mechanism of Vascular Endothelial Growth Factor on the Impairment of Airway Epithelial Function in Asthmatic Mice

作者：Yuanyuan Kong, Yan Chen, Fei Sun, Si-xue Qin, Liang Shi · 发表于：Pharmacognosy Magazine · 年份：2025 · DOI：10.1177/09731296251360559 · 研究领域：Cytokine Signaling Pathways and Interactions、Medicinal Plant Pharmacodynamics Research、Cancer-related molecular mechanisms research

Background Asthma is a chronic respiratory disease featured as destruction of epithelial tight junctions. In order to protect the functional integrity of airway epithelial cells, more active and effective prevention and treatment should be sought. Objectives This study explored the mechanism by which ligustrazine affects vascular endothelial growth factor (VEGF) on the impairment of airway epithelial function in asthmatic mice through the Janus kinase/signal transducer and activator of transcription 5 (JAK/STAT5) signaling pathway. Materials and Methods Asthma model mice were randomly assigned to the model group, tetramethylpyrazine (TMP) low-dose group, medium-dose group, high-dose group, TMP high-dose+α7 nAchR group, TMP high-dose+ruxolitinib group, and TMP high-dose group (through blind selection)+mersalyl group, TMP high-dose+SU56141 group, α7 nAchR+SU56141 group, ruxolitinib+SU56141 group, TMP high-dose+α7 nAchR+SU56141 group. Five animals in each group were given different doses of TMP. Airway ventilation resistance, transepithelial resistance and conductance, reactive oxygen species content, and gene expression of mice in each group were detected; JAK, STAT5, VEGF protein expression, ZO-1 and E-cadherin expression, and hematoxylin and eosin staining were observed. Results Ligustrazine can improve the damaged airway epithelial function of asthmatic mice with the involvement of JAK/STAT5 signaling. Further studies found that inhibiting JAK/STAT5 signaling can improve the...